Terazosin

CAS No.: 63590-64-7

product details:

Purity: 99%

Contact us

Terazosin GMP Manufacturer Global Trade 63590-64-7 with Fast Delivery

  • Molecular Formula: C19H25N5O4
  • Molecular Weight: 387.439
  • Appearance/Colour: white to off-white crystalline powder 
  • Melting Point: 281-283 °C 
  • Boiling Point: 664.5 °C at 760 mmHg 
  • PKA: pKa (0.1N NaOH): 7.1(at 25℃) 
  • Flash Point: 355.7 °C 
  • PSA: 103.04000 
  • Density: 1.332 g/cm3 
  • LogP: 1.64090 

Terazosin(Cas 63590-64-7) Usage

Synthesis

Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)- piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a tetrahydrofuryl radical. It is synthesized in exactly the same manner except using 1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51].

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid concomitant use. Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension when used in combination.

Metabolism

Terazosin is metabolised in the liver; one of the metabolites has antihypertensive activity. Terazosin is excreted in faeces via the bile, and in the urine, as unchanged drug and metabolites.

InChI:InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2/p-1

63590-64-7 Relevant articles

A facile synthesis of [tetrahydrofuran-3H] terazosin

Egan, Judith A.,Souza, Steven M.,Filer, Crist N.

, p. 1881 - 1884 (2004)

An efficient synthesis of [3H] terazosin...

Targeting Influenza A Virus RNA Promoter

Bottini, Angel,De, Surya K.,Wu, Bainan,Tang, Changyan,Varani, Gabriele,Pellecchia, Maurizio

, p. 663 - 673 (2015/03/30)

The emergence of drug-resistant strains ...

THERAPY FOR COMPLICATIONS OF DIABETES

-

, (2009/07/02)

A method for enhancing glycemic control ...

ANTIHYPERTENSIVE THERAPY

-

, (2009/09/08)

A new use of darusentan is provided in p...

Process for the preparation of terazosin hydrocloride dihydrate

-

Page/Page column 2; 3-4, (2008/06/13)

The present invention relates to an impr...

63590-64-7 Process route

1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide
943644-21-1

1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide

terazosin
63590-64-7

terazosin

Conditions
Conditions Yield
With ammonia; In water; at 25 - 45 ℃; for 1h; pH=8.4;
2-chloro-6,7-dimethoxyquinazolin-4-amine
23680-84-4

2-chloro-6,7-dimethoxyquinazolin-4-amine

N-(tetrahydro-2-furoyl)-piperazine
63074-07-7

N-(tetrahydro-2-furoyl)-piperazine

terazosin
63590-64-7

terazosin

Conditions
Conditions Yield
With hydrogenchloride; potassium hydrogencarbonate; In methanol; 2-methoxy-ethanol;

63590-64-7 Upstream products

  • 19237-84-4
    19237-84-4

    prazosin hydrochloride

  • 23680-84-4
    23680-84-4

    2-chloro-6,7-dimethoxyquinazolin-4-amine

  • 63074-07-7
    63074-07-7

    N-(tetrahydro-2-furoyl)-piperazine

  • 943644-21-1
    943644-21-1

    1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide

*Product Name
CasNo
Purity
Quantity
Company name
*Email
*Other Description
*Verification code:
Submit
Purchase Posted Successfully, our staff will contact you within 24 hours.